Johnson & Johnson (JNJ) 99.51 $JNJ
Global Pharmacovigilance Market 2013-2019 - New Opportunities in the $2 Billion Industry
M2 - 1 hr 21 mins ago
Research and Markets (http://www.researchandmarkets.com/research/mzp99x/pharmacovigilance) has announced the addition of the "Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The total market for global pharmacovigilance services is estimated to be USD 2,147.3 million in 2012 and is forecast to grow at a CAGR of 12.9% from 2013 to 2019 Some of the major players profiled in this report include PRA International Inc., Covance Inc., Synowledge LLC, OptumInsight Inc., iMedGlobal, TCS, iGATE Corporation, Cognizant Technology Solutions, Quintiles and others. Today, pharmacovigilance is considered as a continuous process of evaluation in most of the pharmaceutical companies to reduce the risks associated in bringing the new drug in to the market and to improve the safe usage of medicinal products. The proper rules and guidelines for implementation of drug safety monitoring programs has been formulated by various national and international regulatory authorities such as World Health Organization (WHO) and United States Food and Drugs Administration (USFDA). The global pharmacovigilance market has been segmented based on the type of clinical trials phases, type of service providers and by type of methods used in drug safety reporting. Based on the type of service providers, the market has been segmented in to in-house and contract outsourcing services. Among these, contract outsourcing services market accounts for the largest market share in 2012 and expected to continue the same till 2019 owing to the high cost involvement, growing regulatory concerns and requirement of highly qualified professionals for drug safety reporting. Based on type of clinical trials phases, the total market for pharmacovigilance services is categorized into pre-clinical studies, phase I, II, III and IV (post-marketing surveillance services). Among afore-mentioned services, the market for phase IV services accounts for the largest market share in 2012. Scope Clinical Trial Phases - Pre-Clinical Studies - Phase I - Phase II - Phase III - Phase IV - Post-Marketing Surveillance Service Providers - In-House - Contract Outsourcing Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Pharmacovigilance Market Dynamics Chapter 4 Global Pharmacovigilance Market, by Clinical Trial Phases Chapter 5 Global Pharmacovigilance Market, By Type of Methods Chapter 6 Global Pharmacovigilance Market, by Type of Service Providers Chapter 7 Global Pharmacovigilance Market, by Geography Chapter 8 Global Pharmacovigilance Market Share Analysis Chapter 9 Recommendations Chapter 10 Company Profiles - Accenture, Plc - Bristol-Myers Squibb - Clinquest Group B.V. - Cognizant Technology Solutions - Covance, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline (GSK) - iGATE Corporation - iMEDGlobal Corporation - inVentiv Health Inc. - ICON, Plc - Infosys - Johnson and Johnson - Novartis International AG - OptumInsight, Inc. - PRA International, Inc. - Parexel International Corporation - Pfizer, Inc. - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Quantum Solutions India - Quintiles Transnational Corporation - Sanofi Aventis - Synowledge LLC - United BioSource Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/mz...ovigilance
Final Glance: Pharmaceuticals companies
AP - Tue May 06, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Tue May 06, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Can Bristol-Myers Squibb Make a Comeback in 2014?
Cory Renauer, The Motley Fool - Motley Fool - Tue May 06, 1:30PM CDT
So far this year Bristol-Myers Squibb has underperformed the broader market. The impending loss of Abilify and Baraclude exclusivity is weighing on the stock. Luckily, newer commercial stage products and a late-stage cancer therapy are highly...
Midday Glance: Medical Devices companies
AP - Tue May 06, 12:22PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Midday Glance: Pharmaceuticals companies
AP - Tue May 06, 12:22PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Patient Monitoring Device / Equipment / System Market by Product & End-user - Global Forecast to 2018
M2 - Tue May 06, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bflr6j/patient) has announced the addition of the "Patient Monitoring Device / Equipment / System Market by Product & End-user - Global Forecast to 2018" report to their offering. The patient monitoring devices market is segmented into nine major segments, namely, hemodynamic, neurology, cardiac, respiratory, fetal and neonatal, multiparameter, remote patient monitors, temperature, and weight management monitors. The overall patient monitoring devices market was valued as $17.0 billion in 2013 and is poised to grow at a CAGR of 5.5% till 2018. The market is driven by rise in the geriatric population, growing incidences of lifestyle diseases, increased use of home and remote monitors, and technological advancements like portability of equipment. However, the economic crisis and unpredictable reimbursement policies will restrain the growth of this market to an extent. The most fruitful segments for companies to invest in the near future will be neuromonitors, remote patient monitoring (RPM) devices, and respiratory monitors. The cardiac monitors segment is further sub divided into ECG, event monitors, and cardiac output sub segments. ECG was the leading segment owing to expanding old population and growing incidences of cardiac and diseases such as diabetes and hypertension. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Hemodynamic Monitoring Devices 6 Neuromonitoring Devices 7 Cardiac Monitoring Devices 8 Fetal & Neonatal Monitoring Devices 9 Respiratory Monitoring Devices 10 Multi-Parameter Monitoring Devices 11 Remote Patient Monitoring Devices Market 12 Weight Monitoring Devices 13 Temperature Monitoring Devices 14 Geographic Analysis 15 Competitive Landscape 16 Company Profiles Companies Mentioned: - A&D Medical Company Ltd. - AMBU Inc. - Abbott Laboratories - Briggs Healthcare - Cardiocom (Medtronic) - Cardionet, Inc. (Biotelemetry, Inc.) - Carefusion Corporation - Compumedics Limited - Conmed - Contec Medical Systems Co. Ltd. - Covidien - Drager Medical Gmbh - Edwards Lifesciences Corporation - Elekta AB - Fukuda Denshi Company Ltd. - Ge Healthcare - Honeywell International Inc. - Intouch Health - Johnson & Johnson, Inc. - Lifewatch AG - Masimo Corporation - Mindray Medical International Limited - Mortara Instrument, Inc. - Natus - Nihon Kohden - Nonin Medical Inc. - OSI Systems Inc. (Spacelabs Healthcare) - Omron - Robert Bosch Healthcare Inc. - Roche Diagnostics Limited - Royal Philips Healthcare - Schiller AG - Seca Gmbh & Co. Kg. - Siemens Healthcare - Smiths Medical - Welch Allyn - Yokogawa Electric Corporation For more information visit http://www.researchandmarkets.com/research/bflr6j/patient
Early Glance: Pharmaceuticals companies
AP - Tue May 06, 9:34AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Tue May 06, 9:34AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Stock Market News for May 06, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue May 06, 9:06AM CDT
Benchmarks finished in the green on Monday as encouraging services sector data outweighed concerns emanating from escalating Ukraine-Russia geopolitical tension
The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure
at The Street - Tue May 06, 9:00AM CDT
The F-R Rule is still 100% accurate predicting failure for oncology phase III studies undertaken by companies with market caps less than $300 million.
Does Stryker's Skid Offer a Buying Opportunity?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue May 06, 8:30AM CDT
Long-term investing is generally the way to go, but that does not mean that investors shouldn't take advantage of short-term moves that work in their favor. Stryker remains a very well-run company in the med-tech space, with good...
OTC Pharmaceuticals Market in Latin America 2014-2018
PR Newswire Europe - Tue May 06, 6:28AM CDT
DUBLIN, May 6, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "OTC Pharmaceuticals Market in Latin America 2014-2018" [http://www.researchandmarkets.com/research/c3n2v6/otc] report to their offering.
1 Hot Biotech Stock + 1 Extremely Strange Call = 10% Plunge
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon May 05, 5:30PM CDT
Friday's bad market for Pharmacyclics wasn't the outcome of a poor quarter. In fact, just looking at the 1st quarter sales of Imbruvica, the blood cancer drug it shares with Johnson & Johnson , there is no reason to think it won't fulfill...
Johnson & Johnson Announces U.S. "Champions of Care" Program Finalists as Part of 2014 FIFA World Cup Brazil(TM) Sponsorship
PR Newswire - Mon May 05, 2:54PM CDT
Johnson & Johnson, the Official Healthcare Sponsor of the 2014 FIFA World Cup Brazil(TM), announced today the six finalists for the US Champions of Care program, which was created to shine a spotlight on people who go above and beyond to do extraordinary things in caring for others.
Interesting January 2015 Stock Options For JNJ
at The Street - Mon May 05, 11:15AM CDT
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson . So this week we highlight one interesting put contract, and one interesting call contract, from the...
Global Pharmacovigilance Market 2013-2019 - New Opportunities in the $2 Billion Industry
M2 - 1 hr 21 mins ago
Research and Markets (http://www.researchandmarkets.com/research/mzp99x/pharmacovigilance) has announced the addition of the "Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The total market for global pharmacovigilance services is estimated to be USD 2,147.3 million in 2012 and is forecast to grow at a CAGR of 12.9% from 2013 to 2019 Some of the major players profiled in this report include PRA International Inc., Covance Inc., Synowledge LLC, OptumInsight Inc., iMedGlobal, TCS, iGATE Corporation, Cognizant Technology Solutions, Quintiles and others. Today, pharmacovigilance is considered as a continuous process of evaluation in most of the pharmaceutical companies to reduce the risks associated in bringing the new drug in to the market and to improve the safe usage of medicinal products. The proper rules and guidelines for implementation of drug safety monitoring programs has been formulated by various national and international regulatory authorities such as World Health Organization (WHO) and United States Food and Drugs Administration (USFDA). The global pharmacovigilance market has been segmented based on the type of clinical trials phases, type of service providers and by type of methods used in drug safety reporting. Based on the type of service providers, the market has been segmented in to in-house and contract outsourcing services. Among these, contract outsourcing services market accounts for the largest market share in 2012 and expected to continue the same till 2019 owing to the high cost involvement, growing regulatory concerns and requirement of highly qualified professionals for drug safety reporting. Based on type of clinical trials phases, the total market for pharmacovigilance services is categorized into pre-clinical studies, phase I, II, III and IV (post-marketing surveillance services). Among afore-mentioned services, the market for phase IV services accounts for the largest market share in 2012. Scope Clinical Trial Phases - Pre-Clinical Studies - Phase I - Phase II - Phase III - Phase IV - Post-Marketing Surveillance Service Providers - In-House - Contract Outsourcing Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Pharmacovigilance Market Dynamics Chapter 4 Global Pharmacovigilance Market, by Clinical Trial Phases Chapter 5 Global Pharmacovigilance Market, By Type of Methods Chapter 6 Global Pharmacovigilance Market, by Type of Service Providers Chapter 7 Global Pharmacovigilance Market, by Geography Chapter 8 Global Pharmacovigilance Market Share Analysis Chapter 9 Recommendations Chapter 10 Company Profiles - Accenture, Plc - Bristol-Myers Squibb - Clinquest Group B.V. - Cognizant Technology Solutions - Covance, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline (GSK) - iGATE Corporation - iMEDGlobal Corporation - inVentiv Health Inc. - ICON, Plc - Infosys - Johnson and Johnson - Novartis International AG - OptumInsight, Inc. - PRA International, Inc. - Parexel International Corporation - Pfizer, Inc. - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Quantum Solutions India - Quintiles Transnational Corporation - Sanofi Aventis - Synowledge LLC - United BioSource Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/mz...ovigilance
Final Glance: Pharmaceuticals companies
AP - Tue May 06, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Tue May 06, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Can Bristol-Myers Squibb Make a Comeback in 2014?
Cory Renauer, The Motley Fool - Motley Fool - Tue May 06, 1:30PM CDT
So far this year Bristol-Myers Squibb has underperformed the broader market. The impending loss of Abilify and Baraclude exclusivity is weighing on the stock. Luckily, newer commercial stage products and a late-stage cancer therapy are highly...
Midday Glance: Medical Devices companies
AP - Tue May 06, 12:22PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Midday Glance: Pharmaceuticals companies
AP - Tue May 06, 12:22PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Patient Monitoring Device / Equipment / System Market by Product & End-user - Global Forecast to 2018
M2 - Tue May 06, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bflr6j/patient) has announced the addition of the "Patient Monitoring Device / Equipment / System Market by Product & End-user - Global Forecast to 2018" report to their offering. The patient monitoring devices market is segmented into nine major segments, namely, hemodynamic, neurology, cardiac, respiratory, fetal and neonatal, multiparameter, remote patient monitors, temperature, and weight management monitors. The overall patient monitoring devices market was valued as $17.0 billion in 2013 and is poised to grow at a CAGR of 5.5% till 2018. The market is driven by rise in the geriatric population, growing incidences of lifestyle diseases, increased use of home and remote monitors, and technological advancements like portability of equipment. However, the economic crisis and unpredictable reimbursement policies will restrain the growth of this market to an extent. The most fruitful segments for companies to invest in the near future will be neuromonitors, remote patient monitoring (RPM) devices, and respiratory monitors. The cardiac monitors segment is further sub divided into ECG, event monitors, and cardiac output sub segments. ECG was the leading segment owing to expanding old population and growing incidences of cardiac and diseases such as diabetes and hypertension. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Hemodynamic Monitoring Devices 6 Neuromonitoring Devices 7 Cardiac Monitoring Devices 8 Fetal & Neonatal Monitoring Devices 9 Respiratory Monitoring Devices 10 Multi-Parameter Monitoring Devices 11 Remote Patient Monitoring Devices Market 12 Weight Monitoring Devices 13 Temperature Monitoring Devices 14 Geographic Analysis 15 Competitive Landscape 16 Company Profiles Companies Mentioned: - A&D Medical Company Ltd. - AMBU Inc. - Abbott Laboratories - Briggs Healthcare - Cardiocom (Medtronic) - Cardionet, Inc. (Biotelemetry, Inc.) - Carefusion Corporation - Compumedics Limited - Conmed - Contec Medical Systems Co. Ltd. - Covidien - Drager Medical Gmbh - Edwards Lifesciences Corporation - Elekta AB - Fukuda Denshi Company Ltd. - Ge Healthcare - Honeywell International Inc. - Intouch Health - Johnson & Johnson, Inc. - Lifewatch AG - Masimo Corporation - Mindray Medical International Limited - Mortara Instrument, Inc. - Natus - Nihon Kohden - Nonin Medical Inc. - OSI Systems Inc. (Spacelabs Healthcare) - Omron - Robert Bosch Healthcare Inc. - Roche Diagnostics Limited - Royal Philips Healthcare - Schiller AG - Seca Gmbh & Co. Kg. - Siemens Healthcare - Smiths Medical - Welch Allyn - Yokogawa Electric Corporation For more information visit http://www.researchandmarkets.com/research/bflr6j/patient
Early Glance: Pharmaceuticals companies
AP - Tue May 06, 9:34AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Tue May 06, 9:34AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Stock Market News for May 06, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue May 06, 9:06AM CDT
Benchmarks finished in the green on Monday as encouraging services sector data outweighed concerns emanating from escalating Ukraine-Russia geopolitical tension
The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure
at The Street - Tue May 06, 9:00AM CDT
The F-R Rule is still 100% accurate predicting failure for oncology phase III studies undertaken by companies with market caps less than $300 million.
Does Stryker's Skid Offer a Buying Opportunity?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue May 06, 8:30AM CDT
Long-term investing is generally the way to go, but that does not mean that investors shouldn't take advantage of short-term moves that work in their favor. Stryker remains a very well-run company in the med-tech space, with good...
OTC Pharmaceuticals Market in Latin America 2014-2018
PR Newswire Europe - Tue May 06, 6:28AM CDT
DUBLIN, May 6, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "OTC Pharmaceuticals Market in Latin America 2014-2018" [http://www.researchandmarkets.com/research/c3n2v6/otc] report to their offering.
1 Hot Biotech Stock + 1 Extremely Strange Call = 10% Plunge
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon May 05, 5:30PM CDT
Friday's bad market for Pharmacyclics wasn't the outcome of a poor quarter. In fact, just looking at the 1st quarter sales of Imbruvica, the blood cancer drug it shares with Johnson & Johnson , there is no reason to think it won't fulfill...
Johnson & Johnson Announces U.S. "Champions of Care" Program Finalists as Part of 2014 FIFA World Cup Brazil(TM) Sponsorship
PR Newswire - Mon May 05, 2:54PM CDT
Johnson & Johnson, the Official Healthcare Sponsor of the 2014 FIFA World Cup Brazil(TM), announced today the six finalists for the US Champions of Care program, which was created to shine a spotlight on people who go above and beyond to do extraordinary things in caring for others.
Interesting January 2015 Stock Options For JNJ
at The Street - Mon May 05, 11:15AM CDT
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson . So this week we highlight one interesting put contract, and one interesting call contract, from the...
